RGS5 and metabolic dysfunction-associated steatohepatitis: The silence of RGS5 using siRNA effectively attenuated the role of resmetirom in lipid accumulation in the NAFLD/NASH cell model and also restored the activation of the NF-κB and Jak-STAT3 signaling pathways inhibited by the drug treatment.